Biond Biologics and Guangzhou-Israel Biotechnology Fund ('GIBF') Announce Closing of $8 Million Investment and Collaboration

Biond Biologics Ltd., a private clinical-stage biotechnology company based in Israel, has secured an $8 million minority investment from the Guangzhou-Israel Biotechnology Fund (GIBF) to establish a joint venture aimed at enhancing its oncology programs in China. The announcement was made on June 1, 2026, and marks a significant step for Biond as it seeks to leverage GIBF's expertise in the Chinese biotech landscape to accelerate the development of its innovative therapies.

Biond Biologics specializes in developing first-in-class immunotherapies targeting novel pathways within both the innate and adaptive immune systems. The company’s lead programs, BND-67 and BND-22, are at the forefront of its oncology pipeline. BND-67 is a next-generation immunotherapy designed to target CD28 shedding, a mechanism that plays a crucial role in T-cell modulation, while BND-22 is a Phase 2 anti-ILT2 antibody aimed at restoring anti-tumor immunity in patients with cancers that are typically resistant to standard immuno-oncology therapies. The collaboration with GIBF is expected to enhance Biond's clinical execution and expand its strategic initiatives in the rapidly evolving Chinese market.

The Guangzhou-Israel Biotechnology Fund is recognized for its role in advancing innovative life sciences technologies in China. With its deep understanding of the local regulatory environment and clinical development landscape, GIBF is well-positioned to support Biond in navigating the complexities of the Chinese biotech ecosystem. This partnership is anticipated to facilitate not only the acceleration of Biond's lead programs but also the exploration of additional collaborations across Asia, thereby broadening Biond's geographic footprint and enhancing its market presence.

The strategic investment comes at a time when the Chinese biotechnology sector is experiencing robust growth, driven by increased investment and a focus on innovative therapies. The collaboration between Biond and GIBF highlights the potential for cross-border partnerships in the life sciences sector, particularly as companies seek to capitalize on the unique opportunities presented by the Chinese market. The combination of Biond's cutting-edge science and GIBF's local expertise is expected to create significant value for both patients and stakeholders.

Looking ahead, the partnership between Biond Biologics and GIBF may serve as a model for future collaborations between Western biotech firms and Chinese investors. As the demand for innovative cancer therapies continues to rise, this joint venture could play a pivotal role in advancing Biond's promising pipeline while contributing to the overall growth of the biotechnology sector in China. The successful execution of this collaboration may also encourage other companies to explore similar strategic investments, further enhancing the global interconnectedness of the biotech industry.